TXG (TXG)

$30.71
+3.79%
$3.6B
Market Cap
P/E Ratio
2.05
Beta
Dividend Yield
Piotroski 5/9Altman Z 6.4 SafeBeneish M -2.73 CleanROIC−WACC -21.2%

Quantitative Summary

Deterministic

Financial health is average: Piotroski 5/9, Altman Z 6.4. DCF fair value of $11 implies 54% downside based on model assumptions.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The fundamental economics present a stark contradiction between robust top-line expansion and deteriorating capital efficiency. While revenue grew 5.2% year-over-year, supported by an impressive 69.0% gross margin, the company is generating negative net margins of -6.8%, driving ROE to -5.5%. This collapse in profitability is primarily attributable to a sharp decline in operating leverage rather than asset turnover or equity multiplier issues; the DuPont decomposition reveals that weak margins are the sole driver of this underperformance. Consequently, capital allocation has become destructive, evidenced by an ROIC-WACC spread of -21.2%, indicating that returns on invested capital fall significantly below the cost of financing. Although qualitative risk screens show a moderate Piotroski F-Score of 5/9 and a safe Altman Z-Score of 6.4 suggesting low bankruptcy probability, the negative Beneish M-Score hints at potential earnings quality concerns, while the -14.05% annualized Fama-French alpha signals significant underperformance relative to size and value factors.

Valuation metrics reflect these fundamental headwinds with a substantial discount to intrinsic models. The current price implies a DCF fair value of $11, representing a 54.0% downside from the algorithmic baseline. This wide gap suggests the market is pricing in persistent cash flow destruction despite growth narratives that assume high future expansion rates; specifically, the model projects an implied free cash flow growth rate of 20.3% over ten years to justify current valuations, a premise inconsistent with recent margin erosion and negative ROIC. The stock's heavy tilt toward the Growth factor (HML: -0.822) further exposes it to valuation compression if earnings quality does not improve rapidly, as the weak profitability factor score of -0.899 confirms that current operations are failing to generate sustainable economic rents necessary for premium multiples.

Insider activity reinforces skepticism regarding future prospects, with $1,294,013 in net selling over the last 90 days. This outflow coincides with the divergence between strong gross margins and negative bottom-line results, suggesting management may view current operations as less attractive than alternative capital deployments or exit strategies. The combination of a deeply negative ROIC spread, significant insider distribution, and valuation disconnected from realized profitability creates a high-risk environment where any further margin contraction could exacerbate the gap between market price and fundamental reality.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive
Market Price
$30.71
Fair Value
$11
Implied Upside
-64.4%
$11IMPLIED FAIR VALUEOVERVALUEDOVERUNDER
Growth Rate (Y1–5)2%
-10%20%50%
Discount Rate (WACC)17.7%
5%12.5%20%

5-year two-stage DCF. Terminal growth 3%. Default sliders match the pre-computed base case. Drag to explore scenarios. Not investment advice.

Reverse DCFMarket-Implied
20.3%annual FCF growth priced in at $30.71

The growth rate the market implicitly expects over the next 10 years to justify today's price. Compare with historical growth of 5% YoY revenue.

Sensitivity Matrix

TG ↓ / WACC →15.7%17.7%19.7%
2%$12$11$10
3%$12$11$10
4%$13$11$10

Center = base case. Green = >10% upside, Red = >10% downside vs $30.71.

Pre-computed DCF: WACC=17.7%, terminal growth 3%. Fair value $11 (-54.0%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

5/9
Piotroski F-Score
Average — mixed operational signals
6.4
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.73
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

69.0%
Gross Margin
-6.8%
Net Margin
-3.5%
ROIC
17.7%
WACC
ROIC − WACC Spread: -21.2%— Negative spread.
+5.3%
Revenue Growth (YoY)
+76.2%
Earnings Growth (YoY)
130.1M
Free Cash Flow

DuPont Analysis — ROE Decomposition

Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.

-6.8%
Net Profit Margin
NI ÷ Revenue
×
0.62x
Asset Turnover
Revenue ÷ Assets
×
1.31x
Equity Multiplier
Assets ÷ Equity
=
-5.5%
Return on Equity
Balanced ROE composition across margins, turnover, and leverage.

Balance Sheet Health

0.31x
Debt / Equity
4.46x
Current Ratio
-102.5x
Net Debt / EBITDA
5.06%
FCF Yield
3.9M
EBITDA

Insider Activity (Last 90 Days)

Net Insider Flow
-$1M
Net Selling
0
Buy Transactions
6
Sale Transactions
2026-03-24SAXONOV SERGE WILSONSold 8/8 qtrsSale$288,908
2026-03-03SAXONOV SERGE WILSONSold 8/8 qtrsOther2,750 shares
2026-03-02SAXONOV SERGE WILSONSold 8/8 qtrsSale$367,097
2026-02-26SAXONOV SERGE WILSONSold 8/8 qtrsGrant157,895 shares
2026-02-26HINDSON BENJAMIN JSold 8/8 qtrsGrant88,816 shares

Open-market buys vs sells by company insiders. Source: yfinance.

Earnings Surprise History

Q4
✓ Beat
Est: $-0.29
Act: $-0.10
+64.9%
Q3
✓ Beat
Est: $-0.08
Act: $0.48
+702.1%
Q2
✓ Beat
Est: $-0.07
Act: $-0.02
+67.4%
Q1
✓ Beat
Est: $-0.04
Act: $0.07
+276.2%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Risk Profile

68.4%
Annual Volatility
1.75
Sharpe (1Y)
-0.16
Sharpe (3Y)
-88.7%
Max Drawdown (3Y)
-96.5%
Max Drawdown (5Y)

Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fama-French 5-Factor Exposure

Academic factor model decomposition — what's really driving this stock's returns.

1.40
Market β
Mkt-RF
+1.864
Size (SMB)
Small-cap tilt
-0.822
Value (HML)
Growth tilt
-0.899
Profit (RMW)
Weak
+0.651
Invest (CMA)
Conservative
Alpha (annual): -14.05%
R²: 37.9%of variance explained by 5 factors

Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.

Fundamentals

141.5
Forward P/E
PEG Ratio
4.54
Price/Book
3M
Avg Volume
$28.86
52W High
$8.95
52W Low
109%
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$303M
Tracked Passive Exposure
8
ETFs Holding TXG
0.23%
Avg Weight in ETFs
$131B
Total ETF AUM

When investors buy or sell ETFs like ARKG or ARKK, the fund manager is mechanically forced to buy or sell TXG shares regardless of TXG's individual fundamentals. We estimate $303M of passive capital is structurally linked to TXG through 8 tracked ETFs. Passive flows have a limited but growing influence on TXG's daily trading dynamics.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in TXG to visualize passive redemption contagion across ETFs and collateral stocks.

TXG Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
TXGEpicenterVBKETFSPDWETFVHTETFCRSPLow RiskTEMHigh RiskTWSTLow RiskTSLALow RiskBEAMLow Risk
TXG Price Drop (%)0

If TXG (TXG) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies CRISPR THERAPEUTICS AG (CRSP) as the most exposed collateral stock, sharing 2 ETFs with TXG. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 9 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

TXG Ownership Dynamics

Passive funds hold 1 in every 9 TXG shares, reducing daily market volatility.

Ticker
TXG
Total Shares
117M
ETF Lock-Up
10.7%
Display Mode
Total Float Impact
10.7%Locked Float

TXG (TXG) exerts measurable gravity on the passive index market, currently representing 6.2% of the ARK Genomic Revolution ETF (ARKG) and 2.5% of the ARK Innovation ETF (ARKK). Across 9 tracked ETFs, approximately 13M shares (10.7% of float) are held by passive funds and rarely trade on the open market. This level of passive ownership means index rebalances can create outsized volume events.

Float lock-up computed from 9 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

TXG Institutional Volume Profile

252-day volume distribution by price level. The Point of Control (POC) marks the price where the most institutional volume transacted — an implicit support/resistance floor.

TICKER
TXG
PRICE
$30.71
FLOOR (POC)
$12.84
STRENGTH
High
$10$11$1212%$13POC 17%$1410%$15$16$17$187%$197%$217%$227%$23$24$25$26$27$28$29$31$30.71
Focus Zone
Point of Control (POC) Support (below price) Resistance (above price) Current Price

The highest-volume price zone for TXG over the past year sits near $12.84 (17% of 252-day volume). The current price of $30.71 trades 139.3% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (17% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.

Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.

TXG Capital Efficiency

How efficiently does TXG convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$130M
EBITDA
$4M
FCF Conversion
3329%
Reinvestment Rate
-3229%
3329% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
-3.5%
ROIC − WACC Spread
-21.2%

TXG converts 3329% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. However, the ROIC-WACC spread is negative (-21.2%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-048,996$22.43$201,780.28
2026-04-2735,762$22.08$789,624.96
2026-04-247,350$21.42$157,437
2026-04-221$22.97$22.97
2026-04-2017,136$26.08$446,906.88
2026-04-1713,815$25.24$348,690.6
2026-04-1397$23.27$2,257.19
2026-04-1024$23.00$552
2026-04-07424$21.89$9,281.36
2026-03-3129$19.81$574.49
2026-03-25275$19.81$5,447.75
2026-03-2460,436$19.14$1.2M
2026-03-2058,689$18.38$1.1M
2026-03-1951,111$17.35$886,775.85
2026-03-1855,607$18.09$1.0M
2026-03-123$20.46$61.38
2026-03-04142$22.62$3,212.04
2026-03-0245,986$23.05$1.1M
2026-02-2729,654$22.13$656,243.02
2026-02-19130$19.57$2,544.1
2026-02-1737,650$18.12$682,218
2026-02-1174,000$19.15$1.4M
2026-02-035,094$19.95$101,625.3
2026-01-29222$21.08$4,679.76
2026-01-22113$22.68$2,562.84
2026-01-21554$22.05$12,215.7
2026-01-20200$20.52$4,104
2026-01-16164$21.20$3,476.8
2026-01-09499,326$19.29$9.6M
2026-01-0820$19.99$399.8

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Price Correlations

Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.

Peer252-Day (1Y)126-Day (6M)Direction
WTGXXNaNNaN
ILMN0.5790.430Moderate
TMO0.5640.450Moderate
IQV0.5520.440Moderate
A0.5480.406Moderate
MTD0.5330.372Moderate
TWST0.5220.486Moderate
NDSN0.5050.416Moderate
PACB0.5000.525Moderate
PSNL0.4960.524Moderate

Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.

Compare TXG to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.